Arch Biopartners Net Income
| ACHFF Stock | USD 0.63 0.05 8.62% |
As of the 10th of February, Arch Biopartners shows the mean deviation of 3.13, and Risk Adjusted Performance of (0.02). Arch Biopartners technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for thirteen technical drivers for Arch Biopartners, which can be compared to its peers. Please confirm Arch Biopartners coefficient of variation and the relationship between the information ratio and kurtosis to decide if Arch Biopartners is priced correctly, providing market reflects its regular price of 0.63 per share. As Arch Biopartners is a penny stock we also strongly suggest to validate its jensen alpha numbers.
Arch Biopartners' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Arch Biopartners' valuation are provided below:Arch Biopartners does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Arch |
Arch Biopartners 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Arch Biopartners' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Arch Biopartners.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Arch Biopartners on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Arch Biopartners or generate 0.0% return on investment in Arch Biopartners over 90 days. Arch Biopartners is related to or competes with Relief Therapeutics, Relief Therapeutics, Helix BioPharma, Covalon Technologies, Zivo Bioscience, and Vicapsys Life. Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact More
Arch Biopartners Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Arch Biopartners' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Arch Biopartners upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 34.54 | |||
| Value At Risk | (6.82) | |||
| Potential Upside | 6.67 |
Arch Biopartners Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arch Biopartners' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Arch Biopartners' standard deviation. In reality, there are many statistical measures that can use Arch Biopartners historical prices to predict the future Arch Biopartners' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.70) | |||
| Treynor Ratio | (0.19) |
Arch Biopartners February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.18) | |||
| Mean Deviation | 3.13 | |||
| Coefficient Of Variation | (2,526) | |||
| Standard Deviation | 4.81 | |||
| Variance | 23.09 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.70) | |||
| Treynor Ratio | (0.19) | |||
| Maximum Drawdown | 34.54 | |||
| Value At Risk | (6.82) | |||
| Potential Upside | 6.67 | |||
| Skewness | (0.58) | |||
| Kurtosis | 4.91 |
Arch Biopartners Backtested Returns
Arch Biopartners secures Sharpe Ratio (or Efficiency) of -0.0396, which signifies that the company had a -0.0396 % return per unit of standard deviation over the last 3 months. Arch Biopartners exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Arch Biopartners' mean deviation of 3.13, and Risk Adjusted Performance of (0.02) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.07, which signifies a somewhat significant risk relative to the market. Arch Biopartners returns are very sensitive to returns on the market. As the market goes up or down, Arch Biopartners is expected to follow. At this point, Arch Biopartners has a negative expected return of -0.19%. Please make sure to confirm Arch Biopartners' maximum drawdown, rate of daily change, and the relationship between the jensen alpha and kurtosis , to decide if Arch Biopartners performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.55 |
Good reverse predictability
Arch Biopartners has good reverse predictability. Overlapping area represents the amount of predictability between Arch Biopartners time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Arch Biopartners price movement. The serial correlation of -0.55 indicates that about 55.0% of current Arch Biopartners price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.55 | |
| Spearman Rank Test | -0.56 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Arch Biopartners reported net income of (1.39 Million). This is 100.41% lower than that of the Healthcare sector and 101.98% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.24% higher than that of the company.
Arch Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arch Biopartners' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Arch Biopartners could also be used in its relative valuation, which is a method of valuing Arch Biopartners by comparing valuation metrics of similar companies.Arch Biopartners is currently under evaluation in net income category among its peers.
Arch Fundamentals
| Return On Asset | -0.38 | |||
| Profit Margin | (1.46) % | |||
| Operating Margin | (1.03) % | |||
| Current Valuation | 136.63 M | |||
| Shares Outstanding | 62.4 M | |||
| Shares Owned By Insiders | 19.18 % | |||
| Price To Earning | 237.00 X | |||
| Price To Sales | 38.19 X | |||
| Gross Profit | (502.88 K) | |||
| EBITDA | (1.08 M) | |||
| Net Income | (1.39 M) | |||
| Cash And Equivalents | 585.57 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 2.31 M | |||
| Current Ratio | 0.75 X | |||
| Book Value Per Share | (0.07) X | |||
| Cash Flow From Operations | (2.98 M) | |||
| Earnings Per Share | 0.01 X | |||
| Target Price | 4.75 | |||
| Number Of Employees | 11 | |||
| Beta | 1.04 | |||
| Market Capitalization | 120.74 M | |||
| Total Asset | 621.64 K | |||
| Z Score | 27.9 | |||
| Net Asset | 621.64 K |
About Arch Biopartners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arch Biopartners's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arch Biopartners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arch Biopartners based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Arch OTC Stock
Arch Biopartners financial ratios help investors to determine whether Arch OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arch with respect to the benefits of owning Arch Biopartners security.